{
    "clinical_study": {
        "@rank": "3129", 
        "acronym": "SYMPATHY", 
        "arm_group": [
            {
                "arm_group_label": "Renal sympathetic denervation", 
                "arm_group_type": "Experimental", 
                "description": "Catheter-based renal nerve ablation"
            }, 
            {
                "arm_group_label": "Usual care", 
                "arm_group_type": "No Intervention", 
                "description": "Antihypertensive treatment according to guidelines"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to assess whether renal denervation (RD) added to usual care\n      compared to usual care alone reduces blood pressure (BP) as determined with ambulatory BP\n      monitoring (ABPM) after 6 months in subjects with an average day-time systolic BP of at\n      least 135 mmHg as determined with use of ABPM, despite use of three or more BP lowering\n      agents or with documented intolerance or contraindication for to 2 or more of the 4 major\n      classes of antihypertensive drugs (ACEi/ARB, calcium channel blockers, betablockers and\n      diuretics) obstructing use of 3 antihypertensives\n\n      Further aims are to assess the effect of renal denervation on the use of BP lowering agents,\n      to explore the effect of renal denervation in strata of estimated glomerular filtration rate\n      (eGFR) (eGFR 20-60 mL/min per 1.73m2 and eGFR>60 mL/min per 1.73m2) and according to\n      baseline office BP.\n\n      Randomization will be stratified by hospital and eGFR and will be at a 2:1 ratio."
        }, 
        "brief_title": "Renal Sympathetic Denervation as a New Treatment for Therapy Resistant Hypertension", 
        "condition": [
            "Hypertension", 
            "Chronic Kidney Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hypertension", 
                "Kidney Diseases", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Individual has a mean day-time SBP \u2265 135 mmHg, as determined with the use of ABPM,\n             while using 3 or more antihypertensive agents for at least 3 months prior to\n             inclusion or with documented intolerance to 2 or more of the 4 major classes\n             antihypertensive drugs ( ACE/ARB, Calcium channel blocker, Beta Blocker, Diuretic)\n             and no possibility to take 3 anti-hypertensive drugs.\n\n          2. Individual is \u226518 years of age.\n\n        Exclusion Criteria:\n\n          1. Individual is unable or unwilling to sign informed consent.\n\n          2. Individual has a treatable secondary cause of hypertension.\n\n          3. Individual has an eGFR below 20 mL/min/1.73m2 using the Modification of Diet in Renal\n             Disease (MDRD) calculation.\n\n          4. Individual has renal artery anatomy that is ineligible for treatment\n\n          5. Individual has any serious medical condition, which in the opinion of the\n             investigator, may adversely affect the safety and/or effectiveness of the participant\n             or the study.\n\n          6. Individual is pregnant, nursing or planning to be pregnant.\n\n          7. Individual has a known, unresolved history of drug use or alcohol dependency, lacks\n             the ability to comprehend or follow instructions, or would be unlikely or unable to\n             comply with study follow-up requirements.\n\n          8. Individual is currently enrolled in another investigational drug or device trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01850901", 
            "org_study_id": "12-540"
        }, 
        "intervention": {
            "arm_group_label": "Renal sympathetic denervation", 
            "intervention_name": "Renal sympathetic denervation", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hypertension", 
            "Renal denervation", 
            "Sympathetic denervation"
        ], 
        "lastchanged_date": "May 15, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Utrecht", 
                    "country": "Netherlands"
                }, 
                "name": "UMC Utrecht"
            }, 
            "investigator": [
                {
                    "last_name": "Peter J Blankestijn", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Rosa L de Jager", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Esther de Beus", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "2", 
        "official_title": "Renal Sympathetic Denervation as a New Treatment for Therapy Resistant Hypertension - A Multicenter Randomized Controlled Trial", 
        "other_outcome": [
            {
                "description": "Impact on quality of life of RD will be measured with Short-Form 36 and EuroQol-5 Dimensions (EQ-5D) measurement instruments. Assessments at 6 months and during prolonged follow up (total 2 years)", 
                "measure": "Impact on quality of life", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Cost-effectiveness of RD will be calculated. For this purpose, health care and indirect costs will be monitored with use of data from the case report form and questionnaires. Absence from work will be assessed using parts of the Short-Form Health and Labour Questionnaire. Assessments at 6 months and during prolonged follow up (total 2 years)", 
                "measure": "Cost-effectiveness", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "overall_contact": {
            "email": "P.J.Blankestijn@umcutrecht.nl", 
            "last_name": "Peter J Blankestijn, MD, PhD", 
            "phone": "+31307557329"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Netherlands: Medical Ethics Review Committee (METC)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in BP: average day-time systolic blood pressure (SBP) as determined with the use of ambulatory blood pressure-monitoring at 6 months and during prolonged follow up (total 2 years)", 
            "measure": "Change in BP (measured by ABPM)", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01850901"
        }, 
        "responsible_party": {
            "investigator_affiliation": "UMC Utrecht", 
            "investigator_full_name": "P. J. Blankestijn", 
            "investigator_title": "Peter J. Blankestijn, nephrologist", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Change in antihypertensive medication defined as daily defined dose (DDD) of all prescribed drugs after 6 months and during prolonged follow up (total: 2 years)", 
                "measure": "Change in the amount of antihypertensive medication", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "The effect on BP of RD in strata of eGFR: eGFR 20-60 mL/min per 1.73m2 versus eGFR>60 mL/min per 1.73m2 at 6 months after intervention and during prolonged follow up (total 2 years)", 
                "measure": "Change in BP in eGFR strata", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Change in office blood pressure at 6 months after intervention and during follow up (total 2 years)", 
                "measure": "Change in office BP", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "UMC Utrecht", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "ZonMw: The Netherlands Organisation for Health Research and Development", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Medtronic", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "UMC Utrecht", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}